{"filings":[{"id":2051401,"accession_number":"0001386570-26-000042","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2026-08-04T20:03:29+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Niagen Bioscience Q2 net sales $29.8M, net income $1.0M; launches pharmaceutical program targeting rare diseases","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $29.8M ($24.2M Tru Niagen); gross margin 64.8%; net income $1.0M ($0.01 EPS); adjusted EBITDA $3.0M.","Launched Niagen Plus telehealth platform with at-home injection kit; received LegitScript certification for advertising.","Introduced NB4168 for rare genetic diseases targeting Ataxia-Telangiectasia; received FDA Rare Pediatric Disease and EMA Orphan Medicinal Product designations.","Appointed Abhijit Kale as Senior Director of Global External Research to lead pharmaceutical program.","2026 outlook: e-commerce growth 10-15% YoY; ingredient business expected lower; expects increased operating expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":61259000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1334118,"accession_number":"0001386570-26-000035","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2026-06-29T20:30:40+00:00","items":["5.07"],"status":"ready","headline":"Niagen Bioscience announces 2026 annual meeting voting results; all directors elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 8 director nominees elected: Rubin (28.5M for, 16.8M withheld) and Shahbazi (30.5M for, 14.7M withheld) had significant withhold votes.","Ratification of Crowe LLP as auditor for fiscal 2026 passed with 56.2M for, 2.3M against, 158k abstain.","Advisory say-on-pay proposal approved with 43.2M for, 1.9M against, 172k abstain, and 13.3M broker non-votes.","Broker non-votes of 13.3M were recorded on director elections and say-on-pay but not on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92555,"accession_number":"0001386570-26-000031","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Niagen Bioscience Q1 net sales $31.5M (+3% YoY); net income $6.3M up from $5.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Gross margin 63.5%; adjusted EBITDA $3.8M vs $4.9M year ago.","Launched clinician-directed telehealth platform Niagen Plus and first cruise ship clinic partnership.","Completed divestiture of Analytical Reference Standards segment to LGC Standards in Feb 2026.","Board approved $20M share repurchase program; repurchased $2.4M in Q1.","FY 2026 G&A outlook improved to +$3-4M vs prior +$4-5M; sales & marketing investment to rise."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":31474000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103477,"accession_number":"0001386570-26-000017","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Niagen Bioscience increases share repurchase authorization to $20M from $10M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved increase of share repurchase program from $10M to $20M.","Approximately $2.6M of common stock repurchased through March 17, 2026.","Program runs through October 31, 2027, unless modified or terminated.","CEO Rob Fried cited conviction in strategy and long-term value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103476,"accession_number":"0001386570-26-000014","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Niagen Bioscience reports 30% net sales growth to $129.4M in 2025; net income up 103% to $17.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2025 net sales $129.4M (+30% YoY); net income $17.4M (+103%); adjusted EBITDA $20.4M (+139%).","Q4 net sales $33.8M (+16% YoY); Q4 net income $4.1M vs $7.2M prior; Q4 adjusted EBITDA $4.1M (+$0.7M).","Gross margin improved 250 bps to 64.3% for year; cash $64.8M at Dec 31, 2025.","FY 2026 net sales outlook 10-15% growth ex. reference standards segment sold in Feb 2026 for ~$6M.","Acquired foundational NR patent portfolio from Queen’s University Belfast (Dec 2025); launched Tru Niagen Beauty (Nov 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103475,"accession_number":"0001386570-26-000003","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Niagen Bioscience sells ChromaDex Reference Standards business to LGC in all-cash deal","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["All-cash sale closed Feb 24, 2026; buyer is VHG Labs, part of LGC Group.","Divestiture exits non-core activities; focuses on NAD+ science, IP, commercial growth.","Transition services agreement for up to 6 months; service fee recognized as performed.","No purchase price or financial terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119726,"accession_number":"0001386570-25-000030","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Niagen acquires QUB NR patent portfolio; $1M upfront, annual payments through 2038","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["One-time ~$1M payment to QUB for accrued royalties through 2024; annual $500K+£35K through 2038.","Additional one-time payments of $1.5M in 2035 and $2M in 2038 as consideration for patent assignment and release.","QUB assigned all patent rights to ChromaDex; prior JOMA and License Agreement terminated with royalty obligations released.","Acquired portfolio includes composition-of-matter patents for NR salt forms (e.g., NR Malate, NR Tartrate) and global rights.","Niagen now sole owner of core NR IP estate with >90 patents worldwide; CEO cites enhanced control and shareholder protection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119725,"accession_number":"0001386570-25-000025","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Niagen Bioscience authorizes $10M share repurchase program through October 2027","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board authorized up to $10M in common stock repurchases over ~2 years; expires Oct 31, 2027.","Repurchases may occur in open market or private negotiations; no obligation to buy any shares.","CEO Rob Fried states company is \"an excellent investment\" and program is compelling use of capital.","Program may be modified, suspended, or terminated at any time at Board's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119724,"accession_number":"0001386570-25-000021","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Niagen Bioscience Q3 net sales up 33% to $34M, net income $4.6M, raises FY sales growth outlook to 25-30%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $34.0M (+33% YoY); Tru Niagen sales $26.0M (+44% YoY).","Net income $4.6M ($0.06 EPS) vs $1.9M ($0.02 EPS) prior year; adjusted EBITDA $6.4M (+120%).","Gross margin 64.5% (+100 bps); sales & marketing expense as % of sales improved 170 bps to 25.8%.","New FY 2025 outlook: net sales growth 25-30% (from 22-27%); reaffirms momentum in Tru Niagen and Niagen ingredients.","Operational: launched AboutNAD platform, won NAD+ advertising challenge, expanded clinic network to 1,000+ sites."],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":95584000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119723,"accession_number":"0001386570-25-000015","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Niagen Bioscience raises FY2025 net sales growth guidance to 25%-30% YoY","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Full-year 2025 net sales outlook raised to 25%-30% YoY growth from prior 22%-27%.","CEO cites FDA reversal on DSHEA drug preclusion rule for NMN as potential awareness driver.","Press release notes every NMN supplement tested infringes on Niagen's patent portfolio.","Niagen (patented NR) claims superior bioavailability vs. NMN, with three in four NMN products failing label claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136302,"accession_number":"0001386570-25-000011","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Niagen Bioscience Q2 net sales up 37% to $31.1M; raises FY2025 guidance to 22%-27% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $31.1M (+37% YoY); net income $3.6M ($0.05 EPS) vs breakeven in Q2 2024.","Gross margin improved 480 bps to 65.0%; adjusted EBITDA $5.0M, up 221%.","Raises FY2025 revenue growth outlook to 22%-27% (previously 20%-25%).","Secured exclusive worldwide license for Niagen in Parkinson's therapy; NOPARK Phase III trial dosing completed, data expected 2026.","Niagen Plus available in 800+ U.S. wellness clinics (up from 475 in Dec 2024); cash $60.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":61598000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136301,"accession_number":"0001628280-25-036445","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Niagen subsidiary ChromaDex signs exclusive NRCL supply deal with W.R. Grace through 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL); Grace cannot sell to third parties.","Initial term through April 30, 2029, with automatic 12-month renewals unless 90-day non-renewal notice.","ChromaDex must purchase minimum annual quantities and provide rolling 24-month forecasts with first 12 months binding.","Parties will negotiate a royalty-bearing license to Grace's NRCL manufacturing patents upon termination under specified conditions.","2025 product price set at $[***]/kg; each party may propose up to 5% price adjustment twice per year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153419,"accession_number":"0001628280-25-033302","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 4.75M share increase to equity plan and new ESPP at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to 2017 Equity Incentive Plan adds 4,750,000 shares; approved by 53,046,229 votes for.","Employee Stock Purchase Plan approved: 650,000 shares authorized, purchased at 85% of lower of grant/ purchase price.","All eight director nominees elected; Steven Rubin received 12.4M withheld votes, others largely unanimous.","Crowe LLP ratified as independent auditor for FY2025 with 63.4M votes for.","Advisory say-on-pay proposal passed with 54.9M for vs 1.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153418,"accession_number":"0001628280-25-023129","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Niagen Bioscience Q1 net sales $30.5M (+38% YoY), net income $5.1M, raises FY2025 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net sales of $30.5M, up 38% YoY; gross margin 63.4% (+270 bps).","Net income of $5.1M ($0.07 EPS) vs net loss of $0.5M in Q1 2024.","Adjusted EBITDA of $4.9M, up from $0.7M in prior year.","Raised FY2025 outlook: net sales growth 20-25% (prev ~18%); adj G&A $7-8M.","Name change to Niagen Bioscience, ticker NAGE effective Mar 19; new patent for NR salt forms."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":30481000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172167,"accession_number":"0001628280-25-013681","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"ChromaDex rebrands as Niagen Bioscience; Nasdaq ticker becomes NAGE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change from ChromaDex Corporation to Niagen Bioscience, Inc. effective March 19, 2025.","Common stock begins trading under new ticker symbol 'NAGE' on Nasdaq; CUSIP unchanged.","Rebranding reflects focus on flagship Niagen ingredient and NAD+ healthy-aging science; no operational changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172166,"accession_number":"0001628280-25-009785","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex reports record Q4 net sales $29.1M (+37% YoY); first full-year net income $8.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year net sales $99.6M (+19% YoY); Tru Niagen sales $76.8M (+10%), Niagen ingredients $19.2M (+82%).","Q4 net income $7.2M vs $0.1M a year ago; full-year net income $8.6M vs net loss $4.9M in 2023.","Adjusted EBITDA $8.5M in 2024; operating cash flow $12.1M; cash $44.7M with no debt.","G&A expense dropped $6.6M for the year due to $3.5M royalty reversal and $1.3M legal settlement recovery.","FDA granted Orphan Drug and Rare Pediatric Disease Designations for NR; Niagen Plus now at 475+ clinics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172165,"accession_number":"0001628280-25-008691","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ChromaDex amends CEO Fried's contract to $650k base, grants 1.5M PSUs with $15-$50 stock price targets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Base salary increased to $650,000 effective Jan 1, 2025; target bonus raised to 75% of base for FY2025.","CEO granted 1,518,600 PSUs with 7-year performance period; vest at stock price thresholds of $15, $20, $30, $40, $50.","First tranche (759,300 PSUs) vests at $15 VWAP for 60 trading days; subsequent 189,825 each at higher thresholds.","PSUs subject to five-year transfer restriction after vesting; no cash-out feature; forfeiture if targets not met by 2032.","Under termination without cause or for good reason, unvested PSUs remain eligible for 12 months; transfer restrictions lapse."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189142,"accession_number":"0001628280-24-051374","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"ChromaDex appoints Crowe LLP as new independent auditor effective December 13, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved Crowe LLP as independent auditor for fiscal year ending Dec 31, 2024, effective Dec 13, 2024.","No disagreements with prior auditor during fiscal years 2023 and 2022 and subsequent interim period.","No consultations with Crowe regarding application of accounting principles or audit opinion prior to engagement.","Change follows competitive request-for-proposal process conducted by Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189141,"accession_number":"0001628280-24-049951","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ChromaDex obtains waiver of ~$3.5M in accrued royalties from Dartmouth contingent on appeal bond in Elysium case","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dartmouth waives ~$3.5M in accrued unpaid royalties, license fees, and maintenance expenses under exclusive license agreements.","Waiver contingent on ChromaDex securing an Appeal Bond for fee judgment in Delaware patent infringement case against Elysium Health.","ChromaDex executed the Appeal Bond as of December 3, 2024; plans to move to stay execution of fee judgment pending appeal.","No further royalties or payments will be owed to Dartmouth for the licensed patents after effective date of Supplemental Agreement.","Supplemental Agreement supplements prior exclusive license agreements from 2012 and 2014 for Dartmouth-owned U.S. patents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189140,"accession_number":"0001628280-24-048830","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ChromaDex amends ATM sales agreement; adds Roth Capital, removes B. Riley","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment dated Nov 20, 2024 to existing At Market Issuance Sales Agreement of June 12, 2020.","Roth Capital Partners added as Sales Agent; B. Riley Securities removed.","Raymond James & Associates and Roth Capital Partners remain as the two Sales Agents.","No changes to the $0.001 par value common stock or ATM program terms beyond agent roster.","Agreement governs at-the-market equity offering program for ChromaDex common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189139,"accession_number":"0001628280-24-044541","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex posts record Q3: net sales $25.6M (+31% YoY), net income $1.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $25.6M (+31% YoY); gross margin 63.5% (+210 bps).","Net income $1.9M ($0.02 EPS) vs net loss $1.0M ($0.01 loss) in Q3 2023.","Record Adjusted EBITDA $2.9M, up from $0.5M YoY; operating cash $32.4M.","Niagen ingredient sales $6.7M (+368% YoY); Tru Niagen sales $18.1M (+4% YoY).","Expanded Niagen+ to >100 wellness clinics; pursuing FDA IND for Ataxia Telangiectasia."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":70472000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189138,"accession_number":"0001628280-24-042724","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ChromaDex auditor Marcum resigns effective Oct 31 due to conflict from CBIZ merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as independent auditor effective Oct 31, 2024, citing independence concerns from its impending merger with CBIZ Inc.","CBIZ provides HR consulting and health insurance brokerage services to ChromaDex, creating a conflict under independence rules.","Marcum's audit reports for fiscal years 2022 and 2023 contained no adverse opinions or qualifications.","No disagreements or reportable events occurred during the relevant periods; Board and Audit Committee were not involved in the resignation decision.","Company has not yet named a replacement auditor; Marcum's letter to SEC filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205630,"accession_number":"0001628280-24-040982","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ChromaDex appoints Ozan Pamir as CFO effective October 21, 2024; James Lee returns to Controller role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ozan Pamir named CFO effective Oct 21; succeeds interim CFO James Lee who remains Controller.","Annual base salary of $400,000; target bonus 50% of base; option grant with initial value of $360,000.","Pamir previously CFO of 180 Life Sciences; also held investment banking roles at Ventum Financial.","Option vests: 1/3 one-year anniversary, rest over 24 months; severance: 9 months' base salary on termination without cause."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205629,"accession_number":"0001628280-24-035593","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex Q2 net sales up 12% to $22.7M; adjusted EBITDA positive $1.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net sales $22.7M (+12% YoY); Tru Niagen sales $18.6M (+10% YoY).","Gross margin 60.2%; operating expenses down $0.7M YoY to $13.9M.","Net loss approximately breakeven, a $2.2M improvement vs Q2 2023 loss of $2.2M.","Adjusted EBITDA improved to $1.6M from $0.2M in prior year quarter.","FDA Orphan Drug and Rare Pediatric Disease Designation for nicotinamide riboside chloride in Ataxia Telangiectasia."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":44892000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205628,"accession_number":"0001628280-24-031955","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ChromaDex appoints James Lee as Interim CFO after Brianna Gerber resignation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brianna Gerber resigned as CFO and Principal Accounting Officer effective July 12, 2024.","James Lee, Controller since 2009, appointed Interim CFO and Interim Principal Accounting Officer effective July 13, 2024.","Gerber will consult on financial and accounting matters through August 12, 2024 under prior agreement.","Lee holds B.A. in Architecture from UC Berkeley and MBA from UIUC; previously accounting manager at Samsung."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222570,"accession_number":"0001628280-24-029936","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ChromaDex CFO Brianna Gerber resigns effective July 12; consulting transition through Aug 12","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO & CAO Brianna Gerber resigns effective July 12, 2024; company beginning search for replacement.","Post-resignation consulting agreement through Aug 12, 2024; $1,000 consulting fee.","Outstanding stock options and RSUs continue to vest during consulting period per existing equity plan terms.","Gerber confirms resignation is without Good Reason; no severance benefits under employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222569,"accession_number":"0001628280-24-029643","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ChromaDex shareholders elect all 8 director nominees, ratify auditor, and approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected: Jaksch, Fried, Rubin, Yu, Ng, Patrick, Cohen, Shahbazi.","Ratification of Marcum LLP as FY 2024 auditor passed with 49.6M for, 3.4M against, 83,650 abstain.","Advisory approval of named executive officer compensation passed with 40.8M for, 0.9M against, 0.5M abstain.","Broker non-votes of 10.9M reported for director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222568,"accession_number":"0001628280-24-021648","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex Q1 net sales $22.2M, net loss narrows to $0.5M; reiterates 16%+ FY growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $22.2M (-2% YoY); Tru Niagen sales $17.4M. Gross margin 60.7% (+80 bps).","Net loss $0.5M ($0.01 loss per share), improved from $1.9M loss in Q1 2023.","Adjusted EBITDA positive $0.7M vs -$0.1M prior year; cash $27.6M, no debt.","Full-year 2024 outlook reiterated: net sales growth of at least 16%.","Tru Niagen expanded to 700 Vitamin Shoppe stores and 400 Sprouts Farmers Market locations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":22153000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242082,"accession_number":"0001628280-24-009383","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex posts Q4 net income of $0.1M; FY2023 revenue up 16% to $83.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $21.2M (+1% YoY); Tru Niagen sales $17.6M (+9% YoY).","Q4 gross margin 61.0% (up 380 bps); net income $0.1M vs loss of $1.4M prior year.","Full-year net loss improved $11.6M to $4.9M; positive Adjusted EBITDA of $1.9M.","Cash $27.3M, no debt; positive operating cash flow for fourth consecutive quarter.","Exceeded FY2023 outlook for gross margin and G&A; expects accelerated growth in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259486,"accession_number":"0001628280-23-041428","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"ChromaDex extends $10M revolving credit line maturity to Nov 2025; interest rate floor raised to 8.25%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving credit line of up to $10M extended to November 12, 2025; no amounts outstanding as of filing.","Interest rate changed to greater of 8.25% or Prime plus 1%; additional 5% during default event.","Amendment requires maintaining at least 75% of consolidated cash at Western Alliance Bank starting Jan 31, 2024.","$50,000 renewal fee paid; share repurchases limited to $2.5M aggregate during the term.","Quick ratio covenant of 1.15:1.00 added to qualify for streamlined reporting period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259485,"accession_number":"0001628280-23-037816","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex reports Q3 2023 net sales $19.5M (+14% YoY), positive adjusted EBITDA $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net sales $19.5M (+14% YoY); Tru Niagen sales $17.4M (+19% YoY).","Gross margin 61.4% (up 160 bps); net loss $1.0M ($0.01 loss per share).","Adjusted EBITDA positive $0.5M, a $1.7M improvement from Q3 2022.","Cash $26.8M, no debt; positive operating cash flows for third consecutive quarter.","Launched Tru Niagen on iHerb in Aug; launched 1,000mg dosage in Oct; Zesty Paws partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":62374000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276756,"accession_number":"0001628280-23-028555","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex Q2 2023: Net sales $20.3M (+21%), positive Adj EBITDA, raises FY23 guidance to ≥15% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $20.3M, up 21% YoY; Tru Niagen sales $16.9M (+16%).","Net loss narrowed to $2.2M ($0.03/sh) from $6.4M ($0.09/sh) a year ago.","Gross margin 60.8% (+80bps); sales & marketing expense improved 1,830 bps to 29.6% of sales.","Positive Adjusted EBITDA of $0.2M vs negative $4.7M in Q2 2022; positive operating cash flows.","Raised FY2023 revenue outlook by 2.5% to at least 15% YoY growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":42879000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294557,"accession_number":"0001628280-23-022677","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ChromaDex shareholders approve equity plan increase, reject preferred stock authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2017 Equity Incentive Plan, increasing shares available by 3.65M.","Proposal to authorize 5M shares of preferred stock failed (36.2M for, 8.7M against, 181k abstain).","All eight director nominees elected with over 36M votes for each (largest withheld 8.5M for Steven Rubin).","Advisory approval of executive compensation passed with 43.6M for, 1.44M against.","Ratification of Marcum LLP as auditor for FY2023 approved (53.1M for, 3.0M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294556,"accession_number":"0001628280-23-017206","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex Q1 revenue $22.6M (+31% YoY), net loss narrows to $1.9M, raises 2023 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 net sales $22.6M (+31% YoY); Tru Niagen contributed $17.6M.","Gross margin 59.9%; SG&A as % of sales improved to 34.9% from 47.7%.","Net loss $1.9M ($0.03 EPS) vs $7.7M ($0.11 EPS) in Q1 2022; Adjusted EBITDA loss only $0.1M.","Raised conservative end of 2023 revenue outlook to 12.5% growth; generated $2.8M positive operating cash flow.","Operating expenses reduced $2.8M (-15%) driven by lower legal, share-based comp, and severance costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":22556000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315166,"accession_number":"0001628280-23-008497","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"ChromaDex amends bylaws to align with universal proxy rules and DGCL changes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board amended and restated bylaws on March 16, 2023, effective immediately.","Revised advance notice provisions for stockholder proposals and nominations.","Updated to accommodate SEC Rule 14a-19 universal proxy rules.","Addressed DGCL changes regarding stockholder list at meetings.","Other administrative and clarifying changes made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315165,"accession_number":"0001628280-23-006972","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex Q4 revenue $21.0M (+18% YoY), Adj EBITDA turns positive at $0.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $21.0M (+18% YoY); Tru Niagen sales $16.1M (+14% YoY).","Net loss narrowed to $1.4M ($0.02 loss per share) from $5.3M loss a year ago.","Adjusted EBITDA profit $0.4M, a $3.8M improvement vs Q4 2021 loss.","Full year net sales $72.0M (+7%); net loss $16.5M, improved $6.6M YoY.","Signed long-term supply deal with Nestlé Health Science; entered China via Sinopharm Xingsha."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315164,"accession_number":"0001628280-23-000381","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ChromaDex names Brianna Gerber CFO effective Jan 1, 2023; salary $325K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brianna Gerber appointed CFO after serving as interim CFO since August 2022.","Base salary $325,000; discretionary target bonus 50% of base; LTI opportunity 70% of base (Black-Scholes).","Termination w/o cause/good reason: 12-mo salary continuation, pro-rata bonus, COBRA (12 mos), accelerated vesting.","CEO Fried highlights her role in shepherding ChromaDex to EBITDA positive business with fiscal responsibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333500,"accession_number":"0001628280-22-027801","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex Q3 net sales $17.1M, net loss narrows to $1.0M; approaches cash flow breakeven","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.0M ($0.01 loss per share) vs $8.8M loss in Q3 2021; Adjusted EBITDA loss narrowed to $1.2M.","Gross margin 59.8% (down from 61.1% YoY); operating expenses cut $6.1M to $13.3M, driven by lower legal and marketing costs.","Signed long-term supply agreement with Nestlé Health Science with ~$2.0M initial purchase commitment; raised $7.7M from Nestlé and strategic investors.","JV signed to pursue Blue Hat approval for Tru Niagen in Mainland China; clinical study in JACC found Niagen safe in heart failure patients.","Tru Niagen e-commerce sales steady but B2B sales declined due to COVID-19 headwinds and macro factors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":51054000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333499,"accession_number":"0001851734-22-000600","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"ChromaDex expands Nestlé Health Science supply deal to supplements; Nestlé invests $5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New 5-year supply agreement gives Nestlé non-exclusive rights to sell Niagen in dietary supplements, medical nutrition, and functional foods.","Nestlé commits to initial $1.975M Niagen purchase in 2022; ChromaDex eligible for low-single-digit royalties and low-seven-figure milestone payments.","Nestlé purchases 3,816,794 shares of CDXC at ~$1.31/share for $5M in a registered direct offering.","Agreement expands prior 2018 deal; term automatically extends if minimum purchase met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333498,"accession_number":"0001851734-22-000581","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2022-10-03T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"ChromaDex forms China JV for Tru Niagen, sells $3.1M stock to insiders at $1.25/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Taikuk invests $1M for 11% non-voting stake in JV to commercialize Tru Niagen in China; Blue Hat registration required within 24 months.","Prior Term Sheet with Crystal Lake and Pioneer Idea terminated; new structure approved by Audit Committee.","Company sells 2.48M shares at $1.25 for $3.1M to existing holders including CEO Robert Fried; closing expected Oct 7, 2022.","Shares unregistered, sold under Rule 506; Registration Rights Agreement provides for future resale registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350999,"accession_number":"0001851734-22-000422","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"ChromaDex Q2 net sales $16.7M (-5% YoY); CFO Farr terminated, Gerber interim CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $16.7M, down 5% YoY; Tru Niagen sales $14.5M (-6%). Gross margin 60%. Net loss $6.4M ($0.09 loss per share).","CFO Kevin Farr terminated without cause on Aug 10, eff. Aug 12; Brianna Gerber appointed SVP Finance/Interim CFO.","Hamed Shahbazi (CEO of WELL Health) appointed to Board, eff. Aug 9, joins Nominating and Corp Gov committee.","Farr receives separation: 89,189 RSUs, $30,442 lump sum, accelerated equity vesting, pro-rata bonus, 90-day consulting.","Company plans to reduce brand campaigns in H2 2022, shift focus to e-commerce and expense management."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":33991000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368221,"accession_number":"0001628280-22-017489","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"ChromaDex holds 2022 annual meeting; re-elects seven directors, appoints Steven Rubin as Lead Independent Director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["All seven director nominees elected at June 16 annual meeting; votes ranged from ~28.3M to ~37.3M for.","Shareholders ratified Marcum LLP as auditor for FY2022 with 47.7M for, 1.8M against.","Advisory say-on-pay proposal passed with 36.0M for, 1.1M against.","Board appointed Steven Rubin as Lead Independent Director following Kurt Gustafson's departure.","Board committee assignments reconstituted; Rubin chairs Audit, Patrick chairs Compensation, Cohen chairs Nominating."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368220,"accession_number":"0001628280-22-016696","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ChromaDex founder Frank Jaksch resigns as executive director and employee; remains chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Frank L. Jaksch, Jr. resigns as executive director and employee effective June 30, 2022.","He will continue to serve on the Board as Chairman of the Board.","Resignation also covers all officer, employee, director roles at subsidiaries.","Company is ChromaDex Corporation (CDXC)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368219,"accession_number":"0001628280-22-014881","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2022-05-19T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"ChromaDex forms JV to commercialize Tru Niagen in China; gets 71% voting interest","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["JV partners Crystal Lake, Pioneer Idea, Taikuk contribute $1.8M, $1.2M, $1.0M total $4M into the JV.","ChromaDex holds 71% voting interest, appoints 3 of 5 directors; Taikuk gets 11% non-voting interest after $1M fee.","JV to commercialize Tru Niagen and other NR products in Mainland China (excl. HK, Macau, Taiwan) under 20-year term.","Health food (Blue Hat) registration with China SAMR required for broad distribution; must be obtained within 24 months of closing.","JV expects to enter distribution agreement with Sinopharm Xingsha upon regulatory approval; closing targeted by Q3 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368218,"accession_number":"0001628280-22-014063","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex Q1 net sales $17.3M (+18% YoY); net loss $7.7M; adj EBITDA loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $17.3M (+18% YoY); Tru Niagen sales $14.9M (+20% from Q1 2021).","Gross margin 61.0% (down from 62.9%); net loss $7.7M ($0.11 per share) vs $7.4M ($0.12) last year.","Adjusted EBITDA loss (incl legal) $4.5M, a $1.2M improvement from Q1 2021.","Launched Tru Niagen Immune in April 2022; new TV campaign with encouraging early results.","Granted U.S. continuation patent covering NR chloride, malate, and tartrate salts through 2037."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":17259000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368217,"accession_number":"0001628280-22-009420","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2022-04-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ChromaDex announces director retirement and appointment of two new independent directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Block to retire from board at 2022 annual meeting; not due to any disagreement.","Kristin Patrick appointed to board and Nominating Committee; currently EVP/CMO of Claires, Inc.","Ann Cohen appointed to board and Audit Committee; EVP/CFO of The Institute of Internal Auditors, CPA.","Each new director receives 40,000 stock option grant vesting over 3 years, plus annual retainer of $40,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368216,"accession_number":"0001628280-22-009372","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2022-04-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chromadex director Caroline Levy resigns from board and committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Levy resigned effective April 11, 2022; no disagreement with the company cited.","She also stepped down from the Audit Committee and Nominating and Corporate Governance Committee.","No replacement or interim appointment announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368215,"accession_number":"0001628280-22-008931","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2022-04-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Kurt Gustafson not seeking re-election at June 2022 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gustafson notified ChromaDex on April 5, 2022 of decision.","He will remain on Board, Audit Committee, and Compensation Committee until June 2022 meeting.","Departure is not due to any disagreement with the Company on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368214,"accession_number":"0001628280-22-008833","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2022-04-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ChromaDex board member Jeffery Baxter resigns effective April 4, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffery Baxter resigned from the board and its Audit and Nominating/Governance committees on April 4, 2022.","Resignation not due to any disagreement with the company on operations, policies, or practices.","Company has not announced a replacement at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387550,"accession_number":"0001628280-22-006985","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2022-03-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ChromaDex provides 2022 outlook: net sales +15-20% YoY; Tru Niagen revenue $56.7M in 2021","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2021 net sales $67.4M (+14% YoY); Tru Niagen sales $56.7M; gross margin 61.5%.","2022 guidance: net sales +15-20% YoY; gross margin ~60%; R&D spend up ~$2M; G&A down $5-6M.","E-commerce 62% of sales; partnerships expanded with Walmart US and Watsons; new SinoPharm partnership for China.","Cash $28.2M, zero debt; adjusted EBITDA excl. legal loss $(2.5)M in 2021; litigation expense largely behind.","Pipeline includes next-gen NAD precursors (NRH, NAR) with 10+ granted patents; 20+ clinical studies supporting NAD+ boosting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-23T23:59:59+00:00|387550"}